Mary Ann Liebert: AAV Vectors Trigger Innate Immune Pathways
July 11, 2024
July 11, 2024
NEW ROCHELLE, New York, July 11 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
Adeno-associated virus (AAV)-based viral vectors used in human gene therapy can trigger innate immune pathways, leading to the initiation of adaptive immune responses. A new Review article published in the peer-reviewed journal Human Gene Therapy describes the range of likely redundant innate immune pathways that AAV vectors can activate, resulting in an exaggerated adaptive immune r . . .
Adeno-associated virus (AAV)-based viral vectors used in human gene therapy can trigger innate immune pathways, leading to the initiation of adaptive immune responses. A new Review article published in the peer-reviewed journal Human Gene Therapy describes the range of likely redundant innate immune pathways that AAV vectors can activate, resulting in an exaggerated adaptive immune r . . .